LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Home・Listă Acțiuni・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Închisă

Sector Sănătate

48.73 -1.93

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

48.53

Maxim

48.76

Indicatori cheie
By Trading Economics
Venit	14B 1.7B
Vânzări	300M 12B
P/E Medie Sector	14.05 103.001
EPS	2.07
Marjă de profit	13.77
Angajați	34,100
EBITDA	13B 4.4B

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	-1.24 downside

Dividende
By Dow Jones
Următoarele câștiguri	31 oct. 2024
Data viitoare de dividende	30 oct. 2024
Următoarea dată ex-dividende	3 oct. 2024

Statistici piață
By TradingEconomics
Capitalizare de piață	101B
Deschiderea anterioară	50.66
Închiderea anterioară	48.73

Sentimentul știrilor

By Acuity

52%

48%

77 / 365 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

48.11 / 49.92 Suport & Rezistență

Bristol-Myers Squibb Co. Grafic

Știri relevante

26 iul. 2024, 14:08 UTC

Câștiguri

Trending: Bristol Myers Squibb 2Q Adjusted EPS Beat Expectations

26 iul. 2024, 11:54 UTC

Câștiguri

Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales

25 apr. 2024, 14:38 UTC

Câștiguri

Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts

25 apr. 2024, 11:52 UTC

Câștiguri

Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss

16 aug. 2024, 11:30 UTC

Top știri

The Feds Are 'Playing Nice' With Pharma, at Least for Now -- Heard on the Street -- WSJ

8 aug. 2024, 10:30 UTC

Top știri

Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ

29 iul. 2024, 10:30 UTC

Top știri

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

26 iul. 2024, 14:51 UTC

Câștiguri

Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD

26 iul. 2024, 13:53 UTC

Câștiguri

Trending: Bristol Myers Squibb 2Q Adj EPS Beat Expectations

26 iul. 2024, 11:28 UTC

Câștiguri

Bristol Myers Stock Jumps. A Sales Jump for Eliquis Boosts Earnings. -- Barrons.com

26 iul. 2024, 11:14 UTC

Câștiguri

Bristol Myers Squibb Earnings Easily Beat On Cost Cuts; Stock Jumps -- IBD

26 iul. 2024, 11:06 UTC

Câștiguri

Bristol-Myers Squibb 2Q Adj Gross Margin 75.6% >BMY

26 iul. 2024, 11:06 UTC

Câștiguri

Bristol-Myers Squibb 2Q Gross Margin 73.2% >BMY

26 iul. 2024, 11:04 UTC

Câștiguri

Bristol-Myers Squibb Raises 2024 View To EPS 60c-EPS 90c Vs Prior Guidance 40c-70c >BMY

26 iul. 2024, 11:04 UTC

Câștiguri

Bristol-Myers Squibb Now Sees 2024 Total Rev Up Upper End of Low Single-Digit Range >BMY

26 iul. 2024, 10:59 UTC

Câștiguri

Bristol-Myers Squibb 2Q EPS 83c >BMY

26 iul. 2024, 10:59 UTC

Câștiguri

Bristol-Myers Squibb 2Q Net $1.68B >BMY

26 iul. 2024, 10:59 UTC

Câștiguri

Bristol-Myers Squibb 2Q Rev $12.2B >BMY

26 iul. 2024, 10:59 UTC

Câștiguri

Bristol-Myers Squibb 2Q Adj EPS $2.07 >BMY

19 iun. 2024, 05:30 UTC

Top știri

Achiziții, Fuziuni, Preluări

M&A Is Back. 4 Stocks That Could Be Targets. -- Barrons.com

28 mai 2024, 22:51 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

25 apr. 2024, 12:36 UTC

Câștiguri

Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com

25 apr. 2024, 12:31 UTC

Achiziții, Fuziuni, Preluări

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market -- IBD

25 apr. 2024, 11:31 UTC

Câștiguri

AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags -- IBD

25 apr. 2024, 11:06 UTC

Câștiguri

Bristol-Myers Squibb Still Sees 2024 Total Revenue Up Low-Single Digits >BMY

25 apr. 2024, 11:05 UTC

Câștiguri

Bristol-Myers Squibb Cuts 2024 View To EPS 40c-EPS 70c >BMY

25 apr. 2024, 11:05 UTC

Câștiguri

Bristol-Myers: Prioritizing Investing in Key Growth Brands, Optimizing Operations Across Organization >BMY

25 apr. 2024, 11:04 UTC

Câștiguri

Bristol-Myers: Focusing Resources on R&D Programs With Potential to Deliver Greatest Return on Investment >BMY

25 apr. 2024, 11:04 UTC

Câștiguri

Bristol-Myers: Executing Strategic Productivity Initiative Aimed at $1.5B Cost Savings by End 2025 >BMY

25 apr. 2024, 11:03 UTC

Câștiguri

Bristol-Myers Squibb 1Q Adjusted Gross Margin 75.5% >BMY

Comparație

Modificare preț

Bristol-Myers Squibb Co. Așteptări

Obiectiv de preț

By TipRanks

-1.24% jos

Prognoză pe 12 luni

Medie 49.18 USD -1.24%

Maxim 62 USD

Minim 33.1 USD

În baza a 13 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBristol-Myers Squibb Co. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

13 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 13 analiști care au acordat evaluări ale acțiunilor Bristol-Myers Squibb Co. - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

48.11 / 49.92Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

77 / 365 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.